A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Uterine Cervical Dysplasia
Interventions
DRUG

Amolimogene

1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.

DRUG

Amolimogene

3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.

OTHER

Placebo

Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.

Trial Locations (26)

19140

Temple Center for Women's Health, Philadelphia

23456

Tidewater Clinical Research, Virginia Beach

27103

Lyndhurst Gynecologic Associates, Winston-Salem

30912

Medical College of Georgia, Department of Family Medicine, Augusta

33136

University of Florida, Miami, Miami

33409

Comprehensive Clinical Trials LLC, West Palm Beach

33437

Michael Altenbern, MD, Nashville

33472

Visions Clinical Research, Boynton Beach

33613

Insignia Clinical Research, Tampa

34239

Physician Care Clinical Research, Sarasota

35205

University of Alabama, Birmingham

38120

Sarah Cannon Research, Memphis

55455

University of Minnesota, Minneapolis

73104

The University of Oklahoma Health Sciences Center, Center for Research in Women's Health, Oklahoma City

75390

UT Southwestern Medical Center at Dallas, Dallas

80228

Physicians Research Options, LC, Lakewood

83404

Rosemark Women's Care Specialists, Idaho Falls

84062

Physicians' Research Options, Pleasant Grove

84070

Physicians' Research Options, LLC, Sandy City

85032

Arizona Wellness Center for Women/Precision Trials, LLC, Phoenix

85724

University of Arizona, Tucson

87102

Southwest Clinical Research, Albuquerque

89030

Centennial Hills OB-GYN Associaties, North Las Vegas

92108

Medical Center for Clinical Research, San Diego

92262

The Center for Advanced Research and Education, Inc., Palm Springs

92324

Arrowhead Regional Medical Center, Colton

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00264732 - A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix | Biotech Hunter | Biotech Hunter